Open AccessOctreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia: a systematic review
Author(s) -
Maria Rinzivillo,
Ilaria de Felice,
Ludovica Magi,
Bruno Annibale,
Francesco Panzuto
Publication year - 2021
Publication title -
journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.084
H-Index - 39
eISSN - 2219-679X
pISSN - 2078-6891
DOI - 10.21037/jgo-20-292
Subject(s) - medicine , octreotide , everolimus , somatostatin , radionuclide therapy , bevacizumab , oncology , neuroendocrine tumors , combination therapy , pasireotide , chemotherapy , acromegaly , hormone , growth hormone
In the last decades, the incidence of neuroendocrine neoplasia (NEN) increased from 1 to 5 new diagnoses/100,000 persons/year. The synthetic somatostatin analogues (SSAs) represent the first-choice treatment for both functionally active and inactive gastro-enteric-pancreatic NEN. This systematic review examines the role of octreotide long-acting release (LAR) in combination with other therapies for NEN management.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom